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Abstract 
Background & Aims: Type-1 hepatorenal syndrome (HRS) is the most high-risk type 
of renal failure in patients with cirrhosis. Terlipressin and albumin are effective 
treatments for type-1 HRS. However, the effects of acute on chronic liver failure 
(ACLF) grade on response to treatment are not clear. We aimed to identify factors 
associated with response to treatment with terlipressin and albumin in patients with type 
1 HRS (reduction in serum level of creatinine to below 1.5 mg/dl at the end of 
treatment) and factors associated with death within 90 days of HRS diagnosis (90-day 
mortality). 
 
Methods: We performed a retrospective analysis of 4 different cohorts of consecutive 
patients with HRS treated with terlipressin and albumin from February 2007 through 
January 2016 at medical centers in Europe (total, 298 patients). We analyzed 
demographic, clinical, and laboratory data collected before and during treatment; 
patients were followed until death, liver transplantation, or 90 days after HRS diagnosis. 
 
Results: Response to treatment was observed in 53% of patients. Of patients with grade 
1 ACLF, 60% responded to treatment; among those with grade 2 ACLF, 48% 
responded, and among those with grade 3 ACLF, 29% responded (P<.001 for 
comparison between grades). In multivariate analysis, baseline serum level of creatinine 
(odds ratio, 0.23; P=.001) and ACLF grade (odds ratio, 0.63; P=.01) were 
independently associated with response to treatment. Patient age (hazard ratio [HR], 
1.05; P<.001), white blood cell count (HR, 1.51; P=.006), ACLF grade (HR, 2.06; 
P<.001), and no response to treatment (HR, 0.41; P<.001) associated with 90-day 
mortality. 
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Conclusion: In a retrospective analysis of data from 4 cohorts of patients treated for 
type-1 HRS, we found ACLF grade to be the largest determinant of response to 
terlipressin and albumin. ACLF grade affects survival independently of response to 
treatment. New therapeutic strategies should be developed for patients with type-1 HRS 
and extrarenal organ failure. 
 
Keywords: Acute kidney injury; cirrhosis; liver transplantation; hepatorenal syndrome. 
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Introduction 
Type-1 hepatorenal syndrome (HRS) is one of the most life-threatening complications 
in patients with decompensated cirrhosis1. It is characterized by a rapidly progressive 
acute renal failure, frequently triggered by bacterial infections or other precipitating 
events, and is associated with very high short-term mortality rate.  
The pharmacological treatment with terlipressin (or noradrenaline) and albumin is the 
most effective treatment of type-1 HRS2–5. It was introduced in the 1990’s, soon after 
the formulation of the peripheral arterial vasodilation hypothesis, which proposed HRS 
as the extreme expression of a severe splanchnic arterial vasodilation and impairment in 
circulatory function6. Subsequent studies in patients with spontaneous bacterial 
peritonitis (SBP) revealed that HRS occurs in the setting of marked reduction in cardiac 
output proving for the first time that HRS results from a more complex pathogenesis7. 
In addition to arterial vasodilation, left ventricular dysfunction is also a major 
contributor. Therefore, resolution of HRS after pharmacological treatment was proposed 
to be due to a combined effect of terlipressin on systemic vascular resistance and of 
albumin on effective circulating blood volume and cardiac output. This strategy enables 
a resolution of HRS in 40-70% of patients. Important predictors of complete response 
and mortality seem to be serum bilirubin, serum creatinine (sCr) concentration and the 
early response to treatment8,9.  
The characterization of Acute-on-Chronic Liver Failure (ACLF) by the Canonic study 
in 2013, has deeply modified our concepts on the pathogenesis of HRS10. ACLF is a 
syndrome defined by acute decompensation of cirrhosis, single or multiple (2 or more) 
organ failures, severe systemic inflammation and very high short-term mortality 
rate10.Type-1 HRS is, therefore, a special form of ACLF. Patients with decompensated 
cirrhosis without ACLF present severe chronic systemic inflammation probably as 
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consequence of continuous translocation of bacteria and bacterial products from gut 
microbiota to the systemic circulation11. ACLF develops when there is a further acute 
increase in systemic inflammation in response to pro-inflammatory triggers (i.e. 
bacterial infections, acute liver injury or, in patients without identifiable triggers, 
probably an acute burst of bacterial translocation). The current belief is that systemic 
inflammation is the common mechanism of acute decompensation and organ 
dysfunction/failure(s) in patients with decompensated cirrhosis11. As such, a higher 
degree of systemic inflammation was associated with a higher number of organ failures 
and, thus, with a higher grade of ACLF10,12. This profound change of the 
pathophysiological background may affect the efficacy of the treatment of type-1 HRS 
by terlipressin plus albumin in patients with ACLF. However, the potential negative 
impact of the degree of ACLF on the response to the treatment with terlipressin and 
albumin in patients with type-1 HRS has been evaluated only in a very small series of 
patients with sepsis induced HRS13. 
The aim of the current study was, therefore, to assess the impact of severity of ACLF on 
the renal response to terlipressin and albumin in patients with HRS. Secondary aim of 
the study was to assess predictors of 90-day mortality 
 
Patients and methods 
Patients 
The study includes four different cohorts of consecutive patients with HRS treated with 
terlipressin and albumin. Some patients were included in prospective investigations 
already published4,5,10,13. The first cohort includes patients evaluated from February 
2007 to January 2016 at the University Hospital of Padova (Italy), the second cohort 
includes patients evaluated from July 2009 to December 2015 at the Liver Unit, 
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Hospital Clinic of Barcelona (Spain), the third cohort includes patients recruited from 
February to September 2011 in the Canonic study and the fourth cohort included 
patients treated from 2010 to 2015 at the University Hospital of Munster (Germany). 
The protocol was approved by the local ethics committee at each center. 
Inclusion criteria were: a) diagnosis of cirrhosis according to histological, clinical, 
biochemical, ultrasonographic and/or endoscopic findings; b) diagnosis of type-1 HRS 
according to the International Club of Ascites (ICA) criteria14; c) age ≥18 years old. 
Exclusion criteria were: a) hepatocellular carcinoma beyond Milan criteria; b) 
extrahepatic malignancy; c) septic and/or hypovolemic shock; d) proteinuria>500 mg/24 
hours; e) hematuria>50 red blood cells per high-resolution field; f) abnormal renal 
ultrasound; g) severe extrahepatic disease (congestive heart failure stage NYHA≥2, 
chronic obstructive pulmonary disease stage GOLD≥2); h) Treatment of HRS with 
midodrine, octreotide and albumin or norepinephrine and albumin; h) previous liver 
transplant. 
 
Definitions 
Type-1 HRS was defined according to ICA criteria14: a) an increase in sCr of at least 
100% in the previous 14 days up to values above 2.5 mg/dl in a patient with cirrhosis 
and ascites; b) no response (sCr>2 mg/dl) after diuretic withdrawal and albumin 
expansion at the dose of 1gr/kg/day for 2 days; c) absence of signs of parenchymal 
kidney damage (24-hour proteinuria<500 mg; red blood cells in urine<50 per high 
resolution field; normal renal ultrasonography); d) absence of shock and/or treatment 
with nephrotoxic drugs (i.e. iodine contrast media, non-steroidal anti-inflammatory 
drugs, aminoglycosides).  
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Resolution of HRS (or response to treatment) was defined as a reduction of sCr to <1.5 
mg/dl during treatment. 
ACLF was defined according to the European Association for the Study of the Liver-
Chronic Liver Failure (EASL-CLIF) consortium10. Extrahepatic organ failures were 
defined by the CLIF organ failure score, which is a simplified version of the original 
CLIF-SOFA score15. More in detail, liver failure was defined as a bilirubin ≥12 mg/dl; 
coagulation failure as a INR ≥2.5; brain failure as hepatic encephalopathy grade ≥3 
(West Haven criteria); respiratory failure as a SpO2/FiO2 ratio≤214 or a PaO2/FiO2 
ratio≤200 or the need for mechanical ventilation; circulatory failure is defined by as the 
need for vasopressor therapy to achieve an adequate mean arterial pressure.  
ACLF was graded as follows: ACLF-1: HRS alone; ACLF-2: HRS and 1 extra-renal 
organ failure; ACLF-3: HRS and 2 or more extra-renal organ failures. Therefore, by 
definition, all patients with type-1 HRS included had at least ACLF-1. 
 
Design of the study 
Terlipressin was administered at a starting dose of 2 to 3 mg/day administered as 
intravenous boluses (0.5 mg every 4-6 hours) or continuous i.v. infusion. The dose of 
terlipressin was increased in a stepwise manner up to a maximum of 12 mg/day in 
patients without early response to treatment (decrease of sCr to more than 25% of 
pretreatment value after 48-72 of treatment). In patients developing severe side effects 
potentially related to terlipressin the drug was withdrawn. Albumin was administered at 
a loading dose of 1 g/kg/day (corresponding to the second day of differential diagnosis 
of HRS) and 20-40 gr/day the subsequent days. The treatment was continued until 
resolution of HRS (sCr<1.5 mg/dl) and/or the appearance of severe side effects 
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(pulmonary edema, cardiac arrhythmia or severe ischemic complications) up to a 
maximum of 15 days.  
Non-responders to treatment were managed according to standard of care. Renal 
replacement therapy was considered an option when indicated only in patients who were 
candidates to liver transplantation (LT). 
Clinical and laboratory characteristics were collected on the day of first administration 
of terlipressin and albumin (baseline data), on the 3rd day of treatment and at the end of 
treatment. Patients were followed up until death, LT or for a maximum of 90 days. 
 
Statistical analysis 
Results are presented as frequencies and percentages for categorical variables, means 
and SDs for normally distributed continuous variables and median and interquartile 
range for not normally distributed continuous variables. Not normally distributed 
variables were log-transformed when necessary. In univariate analyses, Chi-square test 
was used for categorical variables, Student’s t-test or ANOVA for normal continuous 
variables and Mann-Whitney or Kruskal Wallis test for not normally distributed 
continuous variables. To assess the response to terlipressin and albumin treatment, 
logistic regression models were carried out. Factors showing a clinically and 
statistically significant association to the outcome in univariate analyses were selected 
for the initial model. The final models were fitted by using a step-wise forward method 
based on Likelihood Ratios with the same significance level (p<0.05) for entering and 
dropping variables. Using the final model an estimated probability of response after 
treatment was calculated. The proportional-hazards model for Competing-Risks 
proposed by Fine and Gray16 was used to assess the presence of independent factors of 
mortality. This model was chosen in order to account for LT as an event ‘competing’ 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
with mortality. In all statistical analyses, significance was set at p<0.05. Analyses were 
done with SPSS (version 23.0; SPSS, Inc. Chicago, IL) and SAS (version 9.4; SAS 
Institute Inc.; Cary, NC) statistical packages. 
 
Results 
Study population 
Two-hundred and ninety-eight patients with cirrhosis and HRS were included in the 
study. Supplementary Table 1 illustrates the clinical characteristics of the patients. HRS 
was associated with bacterial infections in 169 patients (68 with SBP). The most 
common extra-renal organ failure was liver failure (27%), followed by coagulation 
failure (13%), brain failure (7%), and respiratory failure (2%). One-hundred and 
seventy-nine patients (60%) had ACLF 1, 91 (31%) ACLF 2, and 28 (9%) ACLF 3. The 
characteristics of the 4 cohorts of patients studied are shown in Supplementary Table 2. 
 
Resolution of HRS 
Patients were treated for a median of 8 days and the median cumulative dose of 
terlipressin was 24 mg (IQR=14–42 mg). Resolution of HRS was observed in 53% of 
the patients. Responders showed significantly lower baseline serum bilirubin (3.3 vs 4.8 
mg/dl; p=0.003), INR (1.6 vs 1.8; p=0.004) and sCr (2.7 vs 3.2 mg/dl; p<0.001) than 
non-responders (Table 1). Response rate showed a stepwise decrease from grade 1 to 
grade 3 ACLF (60, 48 and 29% for ACLF 1, ACLF 2 and grade ACLF 3, respectively; 
p<0.001).  
Mean arterial pressure increased significantly during treatment (79 vs 86 mmHg at day 
3; p<0.001), but no difference was found in delta increase of MAP at day 3 between 
responders and non-responders. Unexpectedly, the delta MAP at day 3 increased in a 
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stepwise fashion from grade 1 to grade 3 ACLF (5, 6 and 13 mmHg, respectively; 
p=0.014). The increase in MAP was retained in responders while MAP dropped in non-
responders at the end of treatment. The delta decrease in sCr at day 3 was significantly 
higher in responders than in non-responders (Table 1). 
Complete sequential data on serum albumin concentration were available in 175 
patients. Although serum albumin increased significantly (p<0.001), the median delta 
increase was very small (0.2 g/dl) (Supplementary Figure 1) and the delta increase of 
albumin on day 3 was not significantly different between responders and non-
responders. 
In the multivariate analysis, only baseline sCr (OR=0.23; p=0.001) and ACLF grade 
(OR=0.63; p=0.01) were found to be independent predictors of response to treatment. 
Figure 1 shows the expected probability of HRS resolution according to baseline sCr 
concentration and ACLF grade. The probability of HRS resolution decreased stepwise 
from ACLF-1 to ACLF-3 at any level of sCr. According to the final model, the 
probability of response to terlipressin plus albumin can be estimated by the following 
equation:  
P= 1/(1 + e-(2.114 - 0.367*sCr - 0.549*ACLF grade)) 
We also explored predictors of response to treatment using variable available on day 3. 
Again, ACLF grade on day 3 (OR=0.55; 95% CI=0.35-0.86; p=0.009) and the delta sCr 
(OR=0.43; 95% CI=0.28-0.67; p<0.001) were found to be the only independent 
predictors of response to terlipressin and albumin. Interestingly, the expected 
probability of HRS resolution was very low (≈10%) in patients with ACLF grade 3 and 
no improvement in sCr (Supplementary Figure 2). 
 
Survival 
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During the 90-day follow up 119 patients died (40%), 50 were transplanted (17%), 123 
completed follow up (41%) and 6 patients were lost to follow up (2%). The cumulative 
incidence of 90-day mortality was 41%. As expected, non-survivors were older and had 
a significant worse liver function than survivors (Table 2). Scores of liver disease such 
as MELD, Child Pugh and CLIF-C ACLF score were significantly higher and serum 
sodium was significant lower in non-survivors than in survivors. There was a non-
significant trend towards a higher white blood cells count in non-survivors than in 
survivors. The cumulative incidence of 90-day mortality increased in a stepwise fashion 
according to ACLF grade (30, 50 and 79% for ACLF 1, ACLF 2 and ACLF 3, 
respectively; p<0.001) (Figure 2A). In univariate analysis, response to treatment was 
also a main determinant of survival. Indeed, the cumulative incidence of mortality was 
significantly lower in responders than in non-responders (28 vs 57%; p<0.001) (Figure 
2B). More in detail, in patients with ACLF grade 1 and 2, responders had a significant 
decrease in 90-day mortality than non-responders (20 vs 47%, p<0.001; 40 vs 60%, 
p=0.018; for grade 1 and 2, respectively), while no difference was observed in patients 
with ACLF grade 3 (71 vs 80%; p=0.201). However, a trend towards an improvement in 
28-day mortality was observed in responders vs non-responders with ACLF grade 3 (43 
vs 80%; p=0.063). Interestingly, mortality rate increased according to ACLF grade both 
in responders and non-responders (Figure 3 panel A and panel B). 
In multivariate analysis, age [HR (95% CI): 1.05 (1.03-1.07); p<0.001], white blood cell 
count [1.51 (1.12-2.02); p=0.006], ACLF grade [2.06 (1.54-2.75); p<0.001] and 
response to treatment (yes/no)[0.41 (0.29-0.60); p<0.001] were found to be independent 
predictors of 90-day mortality. When CLIF-C ACLF score was included in the model, it 
was found to be an independent predictor of survival (HR=1.09; p<0.001) together with 
the response to treatment (HR=0.44; p<0.001). 
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Side effects 
Detailed information about side effects were available in 241 patients (Table 3). One-
hundred and ten patients (46%) developed side effects likely related to treatment with 
terlipressin and albumin. The most common side effects were diarrhea and abdominal 
pain, followed by intestinal ischemia, peripheral ischemia, pulmonary edema and 
angina. The treatment with terlipressin and albumin was withheld in 48 patients (20%).  
 
Discussion 
Our study, which represents the largest investigation on the pharmacological treatment 
of HRS, confirms the two major findings so far described. The first is that the 
combination of terlipressin and albumin is effective resolving HRS in approximately 
50% of patients. The second is that baseline sCr and/or early improvement in sCr are 
accurate predictor of treatment response and patient survival. It has been proposed that 
once severe HRS develops, ischemic tubular lesions and/or intrarenal pathways 
worsening renal hypo-perfusion (i.e. imbalance between the intrarenal synthesis 
vasoconstrictor and vasodilator molecules) maintain or worsen renal failure 
independently of potential positive effects of treatment in cardiovascular function17. On 
this basis, current clinical guidelines propose that early detection and treatment of HRS 
would increase the rate of treatment response and survival in patients with ongoing 
HRS18.  
The most outstanding observation of our study is that severity of ACLF, as estimated by 
the number of extra-renal organ failures, is an additional important factor predicting the 
pharmacological treatment response in patients with HRS. The rate of resolution of 
HRS was 60% in patients without extra-renal organ failure (ACLF-1), of 48% in 
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patients with 1 extra-renal organ failure (ACLF-2), and of only 29% in patients with 2 
or more extra-renal organ failures (ACLF-3).  
Beyond the hypothesis that cholestasis may be responsible for a direct tubular damage 
in patients with liver failure19, a recent study by Clària et al.is of special relevance for 
the interpretation of these data12. They measured the plasma levels of cytokines and 
chemokines as markers of systemic inflammation and the plasma concentration of renin 
and copeptin (a precursor of antidiuretic hormone) as markers of systemic circulatory 
dysfunction in a large series of patients with decompensated cirrhosis with and without 
ACLF. There was a significant increase in the plasma levels in both types of biomarkers 
in patients with ACLF as compared with patients without ACLF12. However, the 
strength of the association of ACLF with biomarkers of systemic inflammation was 
significantly higher. Furthermore, the plasma cytokine levels, but neither renin nor 
copeptin, increased stepwise with the grade of ACLF. Finally, the clinical course 
(resolution, improvement, steady course or worsening of ACLF) correlated significantly 
with systemic inflammation but not with circulatory dysfunction12. Such associations 
were also observed when HRS instead of ACLF was considered.  
The authors’ interpretation of these findings was that, although both systemic 
inflammation and systemic circulatory dysfunction participates in the pathogenesis of 
ACLF (and HRS), systemic inflammation is the main driver of the syndrome. It is well 
known that in addition of reducing organ perfusion as consequence of arterial 
vasodilation and impaired left ventricular function, systemic inflammation can impair 
renal and extra-renal organ function through direct deleterious effects of inflammatory 
mediators on essential tissue and cell homeostatic mechanisms, including local 
microcirculation, mitochondrial function and apoptosis20.  
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Our results suggest that this pathophysiological interpretation may also offer a rational 
explanation for our findings. In patients with HRS and ACLF-1, who have moderate 
increase in systemic inflammation over the chronic inflammation of decompensated 
cirrhosis, cardio-circulatory dysfunction and renal hypo-perfusion may have a 
significant role in ACLF development and, therefore, they are more likely to respond to 
terlipressin and albumin. In contrast, in patients with ACLF-2 and particularly with 
ACLF-3, in whom the increase in systemic inflammation is more intense, the 
predominant mechanism would be a generalized increase in microcirculatory and 
mitochondrial function and cell death, disorders that cannot be sufficiently reversed by 
improving systemic circulatory function. Indeed, despite the increase in mean arterial 
pressure on day 3 was progressively higher moving from patients with ACLF-1 to those 
with ACLF-3, the rate of HRS reversal decreased. 
The combination of the two major predictors of response into two prognostic diagrams 
(Figure 1 and Supplementary Figure 2), disclosed the second important finding of our 
study. It showed that severity of ACLF influences treatment response independently on 
whether sCr was moderately or severely increased, thus supporting the important role 
played by the pathophysiological process leading to ACLF on the effectiveness of 
terlipressin and albumin treatment. These data as well as the effects of HRS reversal on 
survival may have important implications for clinical practice, in particular in patients 
with ACLF grade-3. In fact, the reversal of HRS had a modest short-term survival 
benefit in these patients. Thus, it can be relevant for patients who are eligible to liver 
transplantation while it may be pointless in those who are not. Therefore, the decision to 
treat or not a patient with ACLF grade 3 who is not eligible to liver transplantation 
should be individualized taking into account several factors, including the patient’s will. 
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As in previous studies, early renal response to treatment (delta sCr concentration at day 
3) was an accurate predictor of HRS resolution. We, however, did neither observe 
significant differences between changes in delta mean arterial pressure at day 3 nor in 
delta serum albumin concentration at day 3 and at the end of treatment in patients who 
responded and who did not respond to treatment. Another interesting observation was 
that the increase of serum albumin concentration at the end of treatment was minor in 
the two groups despite of a significant administration of exogenous albumin (an initial 
dose of 1 g per Kg of body weight, followed by 20-40/g/day during treatment). 
Therefore, it is very likely that the current pharmacological treatment of HRS is 
underpowered in relation with the albumin dosage, which, in contrast to terlipressin, is 
not adjusted to response. 
As expected and confirming previous studies, age and response to treatment were 
independent predictors of survival in patients with HRS2,4,5. Other predictors were the 
baseline white blood cells count, which is a sensitive marker of systemic inflammation 
in patients with ACLF, and the ACLF grade. Interestingly, mortality rate increased from 
ACLF-1 to ACLF-3 in patients responding and not responding to treatment, indicating 
that severity of ACLF predict survival more accurately than treatment response21. 
Remarkably, patients with ACLF grade 2 and 3 have a very detrimental prognosis even 
if they respond to terlipressin and albumin, highlighting the need to develop new 
treatments for these patients. 
In summary, severity of renal and of ACLF grade are independent predictors of 
therapeutic response to terlipressin and albumin in patients with HRS. Age, baseline 
white blood cells count, baseline ACLF grade, and therapeutic response are independent 
predictors of survival. These data indicate that the grade of systemic inflammation and 
the presence and number of extra-renal organ failure(s) have a great impact in the 
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clinical course in patients admitted with HRS. New treatments should be explored for 
patients with type-1 HRS looking at systemic inflammation as a potential target. 
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Figure Legend 
Figure 1. Probability of response to treatment with terlipressin and albumin according 
to baseline serum creatinine in patients with ACLF grade 1 (green line), grade 2 (yellow 
line) and grade 3 (red line). 
Legend: ACLF, acute-on-chronic liver failure. 
 
Figure 2. Cumulative incidence of mortality at 90-day according to ACLF grade (Panel 
A) and response to treatment with terlipressin and albumin (panel B). 
Legend: ACLF, acute-on-chronic liver failure. 
 
Figure 3. Cumulative incidence of mortality at 90-day according to ACLF grade in 
responders (Panel A) and nonresponders (panel B) to treatment with terlipressin and 
albumin. 
Legend: ACLF, acute-on-chronic liver failure. 
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terlipressin and albumin 
 
Non-responders 
(N=139) 
Responders 
(N= 159) P-value 
Age (years) – m ±SD 58±9 57±10 0.403 
Gender (Male)– n (%) 103 (74.1) 103 (64.8) 0.082 
Clinical Features    
  Spontaneous bacterial peritonitis – n (%) 21 (16.9) 47 (32.9) 0.003 
  Other infection– n (%) 43 (32.1) 58 (40.0) 0.170 
  Gastrointestinal bleeding– n (%) 13 (9.7) 32 (22.1) 0.005 
  Tense/large ascites – n (%) 75 (57.7) 104 (67.5) 0.087 
  Hepatic encephalopathy – n (%) 58 (43.3) 86 (54.1) 0.065 
  Mean arterial pressure (mmHg) – m ± SD 78±10 79±14 0.455 
  Delta MAP on day 3 (mmHg) – m ± SD 5±12 7±10 0.316 
  MAP at end of treatment (mmHg) – m ± SD 81±13 86±13 0.003 
  Heart Rate (bpm) – m ± SD 75±12 76±14 0.355 
Laboratory data    
  Leukocyte count (x 109/L)– M (IQR) 8.2 (4.7-12.5) 8.2 (5.6-11.6) 0.723 
  Platelet count (x 109/L)– M (IQR) 81 (48-115) 104 (65-167) <0.001 
  Bilirubin (mg/dl) – M (IQR) 4.8 (2.2-20.1) 3.3 (1.5-8.4) 0.003 
  Albumin (g/dl) – M (IQR) 3.0 (2.7-3.4) 3.0 (2.6-3.4) 0.353 
  Delta albumin on day 3 (g/dl) – M (IQR) 0.1 (-0.1 – 0.5) 0.3 (0 – 0.6) 0.113 
  International normalized ratio– M (IQR) 1.8 (1.5-2.2) 1.6 (1.4-1.9) 0.004 
  Serum creatinine (mg/dl) – M (IQR) 3.2 (2.6-3.8) 2.7 (2.4-3.4) <0.001 
  Delta creatinine on day 3 (mg/dl)– M (IQR) -0.4 (-0.9-0.1) -1.0 (-1.6/-0.7) <0.001 
  BUN (mg/dl) – M (IQR) 74 (56-97) 57 (45-76) <0.001 
  Serum sodium (mmol/L) – m ± SD 133±6 132±7 0.666 
Organ Failures– n (%)    
  Liver 49 (35.3) 31 (19.5) 0.002 
  Kidney 139 (100.0) 159 (100.0) - 
  Brain 9 (6.5) 13 (8.2) 0.575 
  Coagulation 26 (18.7) 14 (8.8) 0.012 
  Circulation 0 (0.0) 0 (0.0) - 
  Respiratory 4 (2.9) 2 (1.3) 0.321 
  Number of organ failures – M (IQR) 1 (1-2) 1 (1-2) 0.002 
ACLF Grade – n (%)   0.005 
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  Grade I 72 (51.8) 107 (67.3) 
  Grade II 47 (33.8) 44 (27.7) 
  Grade III 20 (14.4) 8 (5.0) 
Scores    
  MELD– m ± SD 30±7 27±6 <0.001 
  MELD-Na– m ± SD 32±6 29±6 <0.001 
  Child-Pugh– m ± SD 10.2±1.9 10.5±2.0 0.240 
  CLIF-C OF– m ± SD 9±2 9±1 0.005 
  CLIF-C ACLF– m ± SD 47±8 45±7 0.050 
Legend: n, number; m, mean; SD, standard deviation; M, median; IQR, interquartile 
range MAP, mean arterial pressure; ACLF, acute-on-chronic liver failure; MELD, 
model of end stage liver disease; CLIF-C OF, CLIF Consortium organ failure score; 
CLIF-C ACLF, CLIF consortium acute-on-chronic liver failure score. 
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died during the 90-day follow up* 
Variables Survivors (N=123) 
Dead 
(N=119) P-value 
Age (years) – m ±SD 56±9 60±10 0.002 
Gender (Male)– n (%) 84 (68.3) 82 (68.9) 0.918 
Clinical Features 82 (68.3) 88 (74.6) 0.287 
  Spontaneous bacterial peritonitis – n (%) 32 (29.9) 27 (24.3) 0.354 
  Other infection– n (%) 32 (28.6) 50 (43.1) 0.022 
  Gastrointestinal bleeding– n (%) 22 (19.6) 16 (13.8) 0.236 
  Tense/large ascites – n (%) 84 (70.6) 64 (58.2) 0.050 
  Hepatic encephalopathy – n (%) 56 (45.5) 63 (55.3) 0.134 
  Mean arterial pressure (mmHg) – m ± SD 79±14 78±12 0.477 
  Heart Rate (bpm) – m ± SD 76±12 77±15 0.529 
Laboratory data    
  Leukocyte count(x 109/L)– M (IQR) 7.8 (5.2-11.6) 8.8 (5.6-13.8) 0.095 
  Platelet count (x 109/L)– M (IQR) 116 (64-181) 83 (53-120) <0.001 
  Serum bilirubin (mg/dl) – M (IQR) 3.2 (1.4-6.0) 6.7 (2.4-20.0) <0.001 
  Serum albumin (g/dl) – M (IQR) 3.1 (2.7-3.5) 2.9 (2.6-3.3) 0.153 
  International normalized ratio– M (IQR) 1.5 (1.3-1.8) 1.8 (1.5-2.4) <0.001 
  Serum creatinine (mg/dl) – M (IQR) 2.8 (2.5-3.7) 3.0 (2.5-3.6) 0.547 
  BUN (mg/dl) – M (IQR) 59 (48-79) 70 (48-89) 0.079 
  Serum sodium (mmol/L) – m ± SD 134±6 132±7 0.031 
Organ Failures– n (%)    
  Liver 19 (15.5) 47 (39.5) <0.001 
  Kidney 123 (100.0) 119 (100.0) - 
  Brain 10 (8.1) 9 (7.6) 0.870 
  Coagulation 5 (4.1) 28 (23.5) <0.001 
  Circulation 0 (0.0) 0 (0.0) - 
  Respiratory 0 (0.0) 5 (4.2) 0.022 
  Number of organ failures – M (IQR) 1 (1-2) 2 (1-2) <0.001 
ACLF Grade – n (%)   
<0.001 
  Grade I 92 (74.8) 52 (43.7) 
  Grade II 28 (22.8) 46 (38.7) 
  Grade III 3 (2.4) 21 (17.7) 
Scores    
  MELD– m ± SD 27±6 31±7 <0.001 
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  MELD-Na– m ± SD 29±6 33±6 <0.001 
  Child-Pugh– m ± SD 9.9±1.9 10.7±2.0 0.017 
  CLIF-C OF– m ± SD 9±1 10±2 <0.001 
  CLIF-C ACLF– m ± SD 44±6 50±8 <0.001 
Response to treatment – n (%)   
<0.001   No response 35 (28.5) 75 (63) 
  Complete response 88 (71.5) 44 (37.0) 
Legend: n, number; m, mean; SD, standard deviation; M, median; IQR, interquartile 
range ACLF, acute-on-chronic liver failure; MELD, model of end stage liver disease; 
CLIF-C OF, CLIF Consortium organ failure score; CLIF-C ACLF, CLIF consortium 
acute-on-chronic liver failure score.  
*patients transplanted (N=50) or lost to follow up (N=6) were excluded from this 
analysis. 
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Table 3. Side effects of treatment with terlipressin and albumin. 
 N=241* 
Side effects – n (%) 110(45.6) 
   Angina 14(5.8) 
   Peripheral ischemia 22(9.3) 
   Circulatory overload 20(8.3) 
   Diarrhea 59(24.6) 
   Intestinal ischemia 22(9.1) 
   Abdominal pain 49(20.3) 
   Hyponatremia# 14 (7.1) 
   Other 11(4.6) 
Withdrawal – n (%) 48(19.9) 
   Angina 4(8.3) 
   Peripheral ischemia 3(6.3) 
   Circulatory overload 8(16.7) 
   Diarrhea 5(10.4) 
   Intestinal ischemia 5(10.4) 
   Abdominal pain 4(8.3) 
   Other 1(2.1) 
   Combination 18(37.5) 
Legend: n, number; *, 57 patients had no information about side effects; #, defined as 
serum sodium<130 mmol/L in patients with baseline sodium≥130 mmol/L (196 
patients). 3 patients developed severe hyponatremia (serum Na<125 mmol/L) 
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Supplementary Table 1. Demographic, clinical and laboratory characteristics of 
patients. 
Variables  (N=298) 
Age (years) – m ±SD 58±10 
Gender (Male)– n (%) 206(69.1) 
Clinical Features  
  Spontaneous bacterial peritonitis – n (%) 68(25.5) 
  Other infection– n (%) 101(36.2) 
  Gastrointestinal bleeding– n (%) 45(16.1) 
  Tense/large ascites– n (%) 179(63.0) 
  Hepatic encephalopathy– n (%) 144(49.2) 
  Mean arterial pressure (mmHg)– m ± SD 79±16 
  Heart Rate (bpm)– m ± SD 76±13 
Laboratory data  
  Leukocyte count (x 109/L)– M (IQR) 8.2(5.2-11.9) 
  Platelet count (x 109/L)– M (IQR) 93(58-144) 
  Serum bilirubin (mg/dl) – M (IQR) 4.1(1.7-14.3) 
  Serum albumin (g/dl)– M (IQR) 3.0(2.7-3.4) 
  International normalized ratio– M (IQR) 1.7(1.4-2.1) 
  Serum creatinine (mg/dl)– M (IQR) 2.9(2.5-3.6) 
  BUN(mg/dl) – M (IQR) 64(48-85) 
  Serum sodium (mmol/L) – m ± SD 133±7 
Organ Failures– n (%)  
  Liver 80(26.9) 
  Kidney 298(100.0) 
  Brain 22(7.4) 
  Coagulation 40(13.4) 
  Circulation 0(0.0) 
  Respiratory 6(2.0) 
Number of organ failures – M (IQR) 1(1-2) 
ACLF Grade– n (%)  
  Grade I 179(60.1) 
  Grade II 91(30.5) 
  Grade III 28(9.4) 
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Scores  
MELD– m ± SD 29±7 
MELD-Na– m ± SD 31±6 
Child-Pugh– m ± SD 10.3±1.9 
CLIF-C OF– m ± SD 9±2 
CLIF-C ACLF– m ± SD 46±8 
Terlipressin  
  Initial dose (mg/day)– M (IQR) 2(2-3) 
  Days of treatment– M (IQR) 8(6-13) 
Legend: n, number; m, mean; SD, standard deviation; M, median; IQR, interquartile 
range ACLF, acute-on-chronic liver failure; MELD, model of end stage liver disease; 
CLIF-C OF, CLIF Consortium organ failure score; CLIF-C ACLF, CLIF consortium 
acute-on-chronic liver failure score. 
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Supplementary Table 2. Comparison between the 4 groups 
 
PADOVA 
N=76 
CLINIC 
N=44 
CANONIC 
N=57 
MUNSTER 
N=121 
Age (years) – m (SD) 58±10 59±8 56±11 58±9 
Gender (Male) – n (%) 54 (71.1) 36 (81.8) 39 (68.4) 77 (63.6) 
Precipitating events – n (%) 43 (56.6) 30 (68.2) 40 (75.5) 96 (79.3) 
SBP – n (%) 17 (22.4) 10 (22.7) 2 (4.4) 39 (38.2) 
Other infection – n (%) 29 (38.2) 18 (40.9) 10 (17.5) 44 (43.1) 
GI bleeding – n (%) 2 (2.6) 2 (4.6) 3 (5.3) 38 (37.3) 
Other PE – n (%) 7 (9.2) 6 (13.6) 4 (7.0) 5 (4.9) 
WBC – M (IQR) 7.3 (5.2-10.7) 6.7 (4.0-9.4) 9.8 (5.9-15.0) 8.7 (6.2-12.4) 
Platelet – M (IQR) 88 (58-127) 71 (45-96) 75 (44-119) 113 (71-181) 
Bilirubin – M (IQR) 4.6 (2.2-14.6) 6.1 (2.8-24.6) 4.9 (2.3-14.2) 2.5 (1.3-10.3) 
Albumin – M (IQR) 3.1 (2.7-3.5) 3.1 (2.7-3.4) 3.1 (2.7-3.5) 2.9 (2.6-3.3) 
INR – M (IQR) 1.7 (1.5-2.1) 2.0 (1.7-2.8) 1.7 (1.4-2.1) 1.5 (1.3-1.8) 
Creatinine – M (IQR) 3.0 (2.6-3.7) 2.9 (2.5-3.4) 3.2 (2.5-3.9) 2.7 (2.2-3.5) 
Urea – M (IQR) 65 (48-81) 81 (48-101) 79 (53-120) 58 (47-72) 
Na – m ± SD 131±6 129±7 133±6 134±6 
MAP (mmHg) – m ± SD 77±11 73±11 78±10 81±15 
Heart Rate (bpm) – m ± SD 75±13 77±12 78±16 74±12 
Ascites grade (large) – n 
(%) 70 (92.1) 14 (35.9) 21 (43.8) 74 (61.2) 
Encephalopathy – n (%) 33 (43.4) 16 (41.0) 21 (36.8) 74 (61.2) 
MELD – m ± SD 30±6 32±6 30±6 26±7 
MELD-Na – m ± SD 32±5 34±5 32±6 28±6 
Child-Pugh – m ± SD 10.7±1.9 10.5±1.8 8.8±1.9 10.8±1.6 
ACLF Grade – n (%)     
Grade 1 45 (59.2) 23 (52.3) 34 (59.7) 77 (63.6) 
Grade 2 23 (30.3) 12 (27.3) 17 (29.8) 39 (32.2) 
Grade 3 8 (10.5) 9 (20.5) 6 (10.5) 5 (4.1) 
Legend: N, number; m, mean; SD, standard deviation; M, median; IQR, interquartile 
range SBP, spontaneous bacterial peritonitis; GI, gastrointestinal; PE, precipitating 
events; MAP, mean arterial pressure; WBC, white blood cells; INR, international 
normalized ratio; ACLF, acute-on-chronic liver failure; MELD, model of end stage liver 
disease; CLIF-C OF, Chronic Liver Failure Consortium organ failure score; CLIF-C 
ACLF, Chronic Liver Failure Consortium acute-on-chronic liver failure score. 
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Supplementary Figure 1. Albumin concentration at baseline, at day 3 and end of 
treatment with terlipressin and albumin. 
 
Legend: *, p<0.001 vs baseline 
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Supplementary Figure 2. Probability of response to treatment with terlipressin and 
albumin according to delta changes in serum creatinine on day 3 in patients without 
ACLF (blue line), ACLF grade 1 (green line), grade 2 (yellow line) and grade 3 (red 
line) on day 3. 
 
Legend: ACLF, acute-on-chronic liver failure;. Delta serum creatinine=serum creatinine 
on day 3 - serum creatinine on day 0. 
 
 
